Analysis of 3-year visual outcomes in patients geographic atrophy reveals acuity loss in 36 months

News
Article

patient with geographic atrophy visits eye care professional to assess visual acuity following GA diagnosis - Image credit: Adobe Stock / ©peopleimages.com

(Image credit: Adobe Stock / ©peopleimages.com)

A large study that retrospectively analyzed the visual outcomes and rate of development of neovascular age-related macular degeneration (nAMD) in eyes with geographic atrophy (GA) found that GA can cause a loss of 2 to 3 lines of visual acuity (VA) within 36 months of follow-up, according to first author Aumer Shughoury, MD, from Indiana University School of Medicine, Indianapolis.

Shughoury and colleagues analyzed 18,712 eyes with GA identified in the CorEvitas Vestrum Health Retina Database.

The mean patient age at index was 78.6 years, and the mean VA was 67.5 letters (Snellen equivalent 20/45). Among these eyes, 18.9% of eyes developed nAMD within 36 months.

The investigators also reported the following findings:

  1. Eyes with fellow-eye nAMD developed nAMD at more than twice the rate of eyes with fellow-eye GA (relative risk, 2.34; 95% confidence interval [CI], 2.20–2.49).
  2. The mean VA of eyes that did not develop nAMD decreased by 12.4 letters (95% CI, 12.0–12.9) within 36 months.
  3. Older patient age and moderate baseline visual impairment (VA <20/40–20/100) were independently correlated with an accelerated rate of decline. The eyes of the oldest patients with moderate visual impairment experienced the worst outcomes, in that they lost an average of 19.7 letters over 36 months (95% CI, 18.1–21.3).
  4. At the 36-month time point, 70% of eyes had vision below threshold for driving (VA ≤20/40), 42% had low vision (VA ≤20/70), and 23% were legally blind (VA ≤20/200).

The investigators commented that GA is associated with a significant disease burden and cited the lines of vision lost within a 36-month period, the effect of older patient age and moderate baseline visual impairment that were correlated independently with poorer visual outcomes, and the fellow-eye nAMD that was seen to be associated with a 2-fold higher risk of exudative conversion within the short 36 months.

Reference
Shughoury A, Boucher N, Aggarwal N, Ciulla TA. Three-year clinical outcomes in geographic atrophy: an analysis of 18,712 patient eyes. Retina. 2025;45:188-197. doi:10.1097/IAE.0000000000004285
Recent Videos
Sherrol Reynolds, OD, FAAO, values the ophthalmic-optometric collaboration on display at the summit, running from February 14-17, 2025 in San Juan, Puerto Rico.
From new treatments on the horizon for macular degeneration to strengthening comanagement ties, optometrists cite a lot to be excited about in the coming year.
EnVision Summit Co-chairs Sherrol Reynolds, OD, FAAO; Katie Rachon, OD, FAAO, Dipl ABO; Jessica Steen, OD, FAAO, Dipl ABO; and Cecelia Koetting, OD, FAAO, Dipl ABO; express excitement for the upcoming conference and why optometrists should attend.
What was the biggest innovation in eye care in 2024?
Dr Carolyn Majcher chats about GA and posterior uveitis at AAOpt 2024
David Chin Yee, MD, at EyeCon 2024
Dr. Adam Wenick at EyeCon 2024
Katherine Talcott, MD, presenting slides
Katherine Talcott, MD, presenting slides
Emily Chew, MD, outlines her lecture that landed her the Proctor Award at ARVO 2024
© 2025 MJH Life Sciences

All rights reserved.